Glaucoma Therapy
OmniVision GmbH focuses on glaucoma treatment through clinical research in intraocular pressure control, with attention to patients affected by open-angle glaucoma and related forms of elevated eye pressure.
- Brinzolamide and Timolol eye drops
- Brimonidine Tartrate and Timolol eye drops
- Fixed-combination ophthalmic therapy
The sponsor’s research activity in this area is centered on comparative development of generic ophthalmic combinations used in pressure-lowering treatment for chronic glaucoma management.
Ocular Hypertension
The clinical portfolio also includes ocular hypertension, reflecting interest in therapies intended to reduce elevated intraocular pressure before or alongside progression to glaucomatous disease.
- Elevated intraocular pressure
- Pressure-lowering eye care
- Adult ophthalmic treatment
These studies address the therapeutic needs of patients requiring sustained control of eye pressure in routine ophthalmology.
Ophthalmic Generic Medicines
OmniVision GmbH is active in the development of generic eye drop formulations, with research directed toward established ophthalmic fixed-dose combinations used in chronic eye disease care.
- Generic substitution in ophthalmology
- Combination eye drop formulations
- Reference product comparison
This area links pharmaceutical development with therapeutic use in glaucoma and ocular hypertension.
Preservative-Free and Phosphate-Free Eye Treatments
One area of interest is preservative-free and phosphate-free ophthalmic therapy, supporting treatment options designed for long-term use in patients with chronic eye pressure disorders.
- Preservative-free formulations
- Phosphate-free ophthalmic solutions
- Long-term tolerability
These formulations are relevant to ongoing management of intraocular pressure in patients requiring repeated topical treatment.
